A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)


About this study

The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of a single oral administration of CP101 for the prevention of recurrent Clostridioides difficile Infection (CDI) in adult patients. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patient or legal representative voluntarily agreed to participate by signing and dating the written informed consent form after trial has been fully explained.
  • Patient 18 years of age or older.
  • History of recurrent CDI.
  • Current active qualifying CDI episode.
  • Females (assigned at birth) must fulfill at least 1 of the following criteria: 
  • Postmenopausal, defined as amenorrhea ≥ 1 year; or 
    • Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation; or 
    • Abstinent or willing to use adequate contraception from Screening through the week 24 visit.
  • Males (as assigned at birth) must fulfill the following criteria:
    • Abstinent or willing to use adequate contraception from Screening through the Week 24 visit.

Exclusion Criteria:

  • Known stool samples testing positive for enteric pathogens (e.g., Salmonella, Shigella, diarrhoeagenic E. coli, Campylobacter, Giardia) within 28 days prior to Screening.
  • Inability to ingest capsules (e.g., severe nausea, vomiting, gastroparesis, gastric outlet obstruction, dysphagia and/or history of chronic aspiration).
  • Active or suspected ileus, toxic megacolon, or bowel obstruction.
  • Historical or current diagnosis of inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis, indeterminate colitis, or microscopic colitis).
  • Recent diagnosis (< 6 months prior to Screening) of diarrhea-predominant irritable bowel syndrome (post-infection or not related to an enteric infection). Patients with diarrhea-predominant irritable bowel syndrome ≥ 6 months prior to Screening may be randomized following confirmation of eligibility.
  • Current diagnosis of chronic diarrheal illness with pre-CDI baseline diarrhea. This includes but is not limited to celiac disease, bile salt diarrhea, chronic pancreatitis, and short gut syndrome.
  • Past administration of bezlotoxumab (Zinplava™), or past enrollment in a C. difficile vaccine trial within 12 months prior to Randomization.
  • Participation in PRISM3 (CDI-001) or PRISM-EXT (CP101-CDI-E02) or received CP101 at any time in the past.
  • Fecal transplant or other live microbiome therapeutics for any condition, regardless of route of administration within 12 months prior to Randomization.
  • Initiation of any systemic cancer treatment (e.g., chemotherapy, radiotherapy, biologic, immunotherapy, others) for active malignancy that is planned 8 weeks prior to Randomization or during the 8 weeks following Randomization. Patients on maintenance treatment for malignancy may be randomized following confirmation of eligibility.
    • NOTE: Patients on hormone therapy alone are eligible.
  • Known primary or secondary immunodeficiency, including but not limited to, IgA deficiency, common variable immunodeficiency, severe combined immunodeficiency, or human immunodeficiency virus/acquired immune deficiency syndrome.
  • History of solid organ transplantation or stem cell transplant.
  • Initiation or dose escalation of systemic immunosuppressive agents, at the discretion of the Investigator, for any condition during the 8 weeks prior to Randomization or planned during the 8 weeks following Randomization. Examples may include but are not limited to corticosteroid agents given orally or intravenously, cyclosporine, tacrolimus, or tumor necrosis factor inhibitors. Patients on stable low dose of systemic immunosuppressive agents or short courses (< 2 weeks) may be randomized following confirmation of eligibility.
  • Major intra-abdominal surgery (e.g., bowel resection) within the past 60 days prior to Screening (excluding appendectomy or cholecystectomy)and/or planned invasive surgery/hospitalization during the trial.
  • History of total colectomy or ileostomy.
  • Use of a systemic antibiotic for any condition (other than CDI) during the Screening period, or any anticipated use of a systemic antibiotic for any condition other than CDI during the trial for 8 weeks after Randomization. This includes patients who have a known medical procedure that requires antibiotic prophylaxis (e.g., elective surgical procedure or dental procedure requiring prophylactic antibiotics) scheduled during the trial.
  • Active drug, chemical, or alcohol dependency as determined by the Investigator through history or optional toxicology screen.
  • Enrollment in any other investigational drug, device, or observational trial within 30 days or 5 half-lives of the last dose, prior to Randomization (Day 1) or at any time during this trial.
  • Pregnant, breast-feeding, or planning to become pregnant during the trial.
  • Clinically significant abnormal laboratory values including, but not limited to, white blood cell count ≥ 15 × 10^9/L, absolute neutrophil count of < 1 × 10^9 neutrophils/L, or laboratory evidence of acute kidney injury at Investigators discretion, at Screening.
  • Screening nasopharyngeal PCR test is positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • Any acute, chronic, or unstable medical comorbidity, psychiatric, social, or other circumstances that, in the opinion of the Investigator, may interfere with trial compliance, completion, or accurate assessment of trial outcomes/safety. Examples include but not limited to acute myocardial infarction, acute stroke, uncompensated congestive heart failure, or decompensated liver disease.
    • NOTE: Trial patients may be screened while an inpatient in an acute care facility/hospital but must be discharged from inpatient medical admission prior to Randomization.
  • Life expectancy < 24 weeks.
  • Known hypersensitivity to CP101 or any component of its formulation or history of severe adverse reactions or other common drug class effects during prior exposure to similar compounds per the judgment of the investigator.

Eligibility last updated 2/1/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Sahil Khanna, M.B.B.S., M.S.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions